22091-36-7

Usage

Uses

Used in Pharmaceutical Industry:
4-(CHLOROMETHYL)-2-(4-CHLOROPHENYL)-1,3-OXAZOLE is used as a potential therapeutic agent for its anti-inflammatory, anti-cancer, and antimicrobial properties. Its ability to modulate various biological pathways and target specific cellular processes makes it a promising candidate for the development of new drugs.
Used in Organic Synthesis:
Due to its heterocyclic nature and functional groups, 4-(CHLOROMETHYL)-2-(4-CHLOROPHENYL)-1,3-OXAZOLE can also be utilized as a building block in organic synthesis. This allows for the creation of a variety of new compounds with potential applications in various fields, including pharmaceuticals, agrochemicals, and materials science.

InChI:InChI=1/C10H7Cl2NO/c11-5-9-6-14-10(13-9)7-1-3-8(12)4-2-7/h1-4,6H,5H2

Upstream product

• 22087-22-5 [2-(4-chloro-phenyl)-oxazol-4-yl]-methanol 
• 104-88-1 4-chlorobenzaldehyde 
• 74-11-3 para-chlorobenzoic acid 
• 122-01-0 4-chloro-benzoyl chloride 

Downstream Products

• 36841-55-1 5-bromo-4-chloromethyl-2-(4-chloro-phenyl)-oxazole 
• 36841-64-2 4-chloromethyl-2-(4-chloro-3-nitro-phenyl)-oxazole 
• 59398-91-3 2-(4-chloro-phenyl)-oxazole-4-carbaldehyde 
• 22087-22-5 [2-(4-chloro-phenyl)-oxazol-4-yl]-methanol 
• 33162-10-6 4-(iodomethyl)-2-(4-chlorophenyl)oxazole 
• 109544-03-8 2-[[2-(4-chlorophenyl)-4-oxazolyl]methoxy]-2-methyl-propionic acid 
• 36841-60-8 [5-bromo-2-(4-chloro-phenyl)-oxazol-4-yl]-methanol 
• 59398-96-8 5-bromo-2-(4-chloro-phenyl)-oxazole-4-carbaldehyde 
• 36841-66-4 5-bromo-4-chloromethyl-2-(4-chloro-3-nitro-phenyl)-oxazole 
• 1198211-96-9 2-({[2-(4-Chlorophenyl)-1,3-oxazol-4-yl]methyl}sulphanyl)-4-[4-(2-hydroxyethoxy)phenyl]-6-methoxypyridine-3,5-dicarbonitrile 
• 1187542-88-6 2-Amino-6-([2-(4-chlorophenyl)-1,3-oxazol-4-yl]methylsulfanyl)-4-(1,3-thiazol-5-yl)pyridine-3,5-dicarbonitrile 
• 1187542-86-4 2-Amino-6-([2-(4-chlorophenyl)-1,3-oxazol-4-yl]methylsulfanyl)-4-(1,3-thiazol-4-yl)pyridine-3,5-dicarbonitrile 
• 1107662-17-8 2-Amino-6-({[2-(4-chlorophenyl)-1,3-oxazol-4-yl]methyl}sulfanyl)-4-(4-{[(2S)-2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitrile 
• 1107662-18-9 2-amino-6-({[2-(4-chlorophenyl)-1,3-oxazol-4-yl]methyl}sulfanyl)-4-(4-{[(2R)-2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitrile 

Relevant academic research and scientific papers

Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi- and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb.

Synthesis and bioactivity of novel pyrazole oxime derivatives containing oxazole ring

Abstract A series of novel pyrazole oxime derivatives containing oxazole ring were designed and synthesized. The title compounds were structurally confirmed by 1H NMR, 13C NMR spectra and elemental analyses. Preliminary bioassay results showed that some of the title compounds displayed promising fungicidal activity besides insecticidal and acaricidal activity. Particularly, compound 8c exhibited potent fungicidal activity against cucumber Pseudoperonospora cubensis beyond good insecticidal activity against Aphis craccivora and Nilaparvata lugens.

Agonists for the adenosine A1 receptor with tunable residence time. a case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines

We report the synthesis and evaluation of previously unreported 4-amino-6-aryl-5-cyano-2-thiopyrimidines as selective human adenosine A 1 receptor (hA1AR) agonists with tunable binding kinetics, this without affecting their nanomolar affinity for the target receptor. They show a very diverse range of kinetic profiles (from 1 min (compound 52) to 1 h (compound 43)), and their structure-affinity relationships (SAR) and structure-kinetics relationships (SKR) were established. When put in perspective with the increasing importance of binding kinetics in drug discovery, these results bring new evidence of the consequences of affinity-only driven selection of drug candidates, that is, the potential elimination of slightly less active compounds that may display preferable binding kinetics.

SUBSTITUTED ARYLOXAZOLES AND THEIR USE

The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE

The present application relates to novel cycloalkoxy-substituted 4-phenyl-3,5-dicyanopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS

Disclosed are isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for use treating in mammals suffering from psychiatric disorders such as, for example, depression, generalized anxiety, social phobia, panic disorder, and sleep disorders.

ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION

Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.